Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00295984 · ClinicalTrials.gov registry record · Phase 2
Nicotine Skin Patch in Treating Patients With Kaposi's Sarcoma
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
NCT00295984: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00295984 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 24 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00295984, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
Study Summary
RATIONALE: Nicotine may stimulate the immune system to kill Kaposi's sarcoma cells. PURPOSE: This phase II trial is studying the side effects and how well the nicotine skin patch works in treating patients with Kaposi's sarcoma.
Interventions
- DRUG nicotine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2006-03 |
| Est. Completion | 2006-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00295984
The ClinicalTrials.gov registry entry for NCT00295984 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which nicotine is the first listed.
NCT00295984 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00295984 about?
NCT00295984 is a clinical study titled "Nicotine Skin Patch in Treating Patients With Kaposi's Sarcoma". RATIONALE: Nicotine may stimulate the immune system to kill Kaposi's sarcoma cells. PURPOSE: This phase II trial is studying the side effects and how well the nicotine skin patch works in treating patients with Kaposi's sarcoma.
What is the current status of trial NCT00295984?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2006-03. Estimated completion is 2006-08.
What interventions are being tested in trial NCT00295984?
The interventions under investigation include: nicotine (DRUG).
Who is sponsoring clinical trial NCT00295984?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.